Financial cost of early rheumatoid arthritis in the first year medical attention: three clinical scenarios.
Abstract
Introduction. In Colombia, the cost burden of chronic diseases is not well known, either globally or in localized areas of the health system. Rheumatoid arthritis is one of most common chronic diseases, and represents a high cost for the health system.Objective. The direct medical costs were estimated for rheumatoid arthritis patients in the in the first year of diagnosis at a level 3 university hospital in Colombia.
Materials and methods. Three therapy settings for early rheumatoid arthritis patients were established in the first year of diagnosis according to national and international guidelines. Each setting included treatment with disease-modifying anti-rheumatic drugs or biologic therapy based on disease severity as measured by Disease Activity Score 28. All direct medical costs were included: specialized medical care, diagnostic tests and drugs. Cost information was obtained from the Central Military Hospital finance department in Bogotá and the national manual of drug prices based on the “Farmaprecios” 2007 guide, a reference in general use by health institutions.
Results. The average of cost of medical care in patients with mild, moderate and severe disease was US$1,689, $1,805 and $23,441 respectively. The recommended retail prices of the medicines published in “Farmaprecios” was US$ 1,418, $1,821 and $31,931. When the charges levied by several major health institutions were compared, substantial increases were noted, US$ 4,936, $ 7,716 and $ 123,661, respectively. Drug costs represented 86% of total cost, laboratory costs were 10% and medical attention was only 4%.
Conclusions. Drugs costs were the principal component of the total direct medical cost, and it increased 40 times when a biological therapy is used. Complete economic evaluation studies are necesary to estimate the viability and clinical relevance of biological therapy for early rheumatoid arthritis.
Downloads
References
1. Guzmán R, Restrepo J. Artritis reumatoide temprana. Rev Colomb Reumatol. 2002;9:171-5.
2. Choy EH, Panayi GS. Cytokine pathways, and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-16.
3. Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical cost in early rheumatoid arthritis. Arthritis Rheum. 2001;44:528-34.
4. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007:21:27-42.
5. Rovira J. Evaluación económica en salud: de la investigación a la toma de decisiones. Rev Esp Salud Pública. 2004;78:293-5.
6. Mora C, González A, Quintana G. Guía de manejo artritis reumatoide temprana en un Hospital Universitario de Colombia. Rev Colomb Reumatol. 2008;15:79-91.
7. Combe B, Landewe R, Lukas C, Bolosiu H D, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.
8. Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (the first 2 years). Rheumatology. 2006;45:1167-9.
9. Vinicio C, Chalem P, Londoño L, Restrepo J, Iglesias A, Vélez P, et al. Primer consenso colombiano sobre el tratamiento de la artritis reumatoide temprana. Rev Col Reumatol. 2002;9:323-31.
10. Loët X, Berthelot J M, Cantagrel A, Combe B, De Bandt M, Fautrel B, et al. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis. 2006;65:45-50.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315- 24.
12. Byford S, Torgerson D, Raftery J. Economic note: Cost of illness studies. BMJ. 2000;320;1335.
13. Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine. 2004;71:518-24.
14. Michaud K, Messer J, Choi H, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis a three-year study of 7,527 patients. Arthritis Rheum. 2003;48:2750-62.
15. Kavanaugh A. The pharmacoeconomics of newer therapeutics for rheumatic diseases. Rheum Dis Clin North Am. 2006;32:45-56.
16. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology. 2000;39:28-33.
17. Pineda-Tamayo R, Arcila G, Restrepo P, Tobón GJ, Camargo JF, Anaya JM. Costos médicos directos de la artritis reumatoide temprana. Rev Colomb Reumatol. 2004;11:89-96.
18. Delgado-Vega A, Martín J, Granados J, Anaya JM. Epidemiología genética de la artritis reumatoide: ¿qué esperar de América Latina? Biomédica. 2006;26:562-84.
Some similar items:
- Constanza Pardo, Ricardo Cendales, Survival analysis of cervical cancer patients , Biomedica: Vol. 29 No. 3 (2009)
- Raúl Murillo, Ricardo Cendales, Carolina Wiesner, Marion Piñeros, Sandra Tovar, Effectiveness of cytology-based cervical cancer screening in the Colombian health system , Biomedica: Vol. 29 No. 3 (2009)
- Sandra Lorena Girón, Julio César Mateus, Fabián Méndez, Impact of an open waste disposal site on the occurrence of respiratory symptoms and on health care costs of children , Biomedica: Vol. 29 No. 3 (2009)
- José Joaquín Carvajal, Ligia Inés Moncada, Mauricio Humberto Rodríguez, Ligia del Pilar Pérez, Víctor Alberto Olano, Characterization of Aedes albopictus (Skuse, 1894) (Diptera:Culicidae) larval habitats near the Amazon River in Colombia , Biomedica: Vol. 29 No. 3 (2009)
- Andrés Páez, Gloria Rey, Carlos Agudelo, Alvaro Dulce, Edgar Parra, Hernando Díaz-Granados, Damaris Heredia, Luis Polo, Outbreak of urban rabies transmitted by dogs in Santa Marta, northern Colombia , Biomedica: Vol. 29 No. 3 (2009)
- Patricia Escobar, Katherine Paola Luna, Indira Paola Hernández, César Mauricio Rueda, María Magdalena Zorro, Simon L. Croft, In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole , Biomedica: Vol. 29 No. 3 (2009)
- Gustavo Pradilla, Julio César Mantilla, Reynaldo Badillo, Human rabies encephalitis by a vampire bat bite in an urban area of Colombia , Biomedica: Vol. 29 No. 2 (2009)
- Mauricio Beltrán, María Cristina Navas, María Patricia Arbeláez, Jorge Donado, Sergio Jaramillo, Fernando De la Hoz, Cecilia Estrada, Lucía del Pilar Cortés, Amalia de Maldonado, Gloria Rey, Seroprevalence of hepatitis B virus and human immunodeficiency virus infection in a population of multiply-transfused patients in Colombia , Biomedica: Vol. 29 No. 2 (2009)
- Rosa Magdalena Uscátegui, Adriana M. Correa, Jaime Carmona-Fonseca, Changes in retinol, hemoglobin and ferritin concentrations in Colombian children with malaria , Biomedica: Vol. 29 No. 2 (2009)
- Claudia M.E. Romero-Vivas, Luis Eduardo Castro, Lila Visbal, Ana María Santos, Esther Díaz, Cutaneous myiasis by Cochliomyia hominivorax (Coquerel) (Díptera Calliphoridae) in Hospital Universidad del Norte, Soledad, Atlántico , Biomedica: Vol. 29 No. 1 (2009)
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |